Payment overview · 2025
General Payments
$502.13
21 reported records · 8 companies
Healthcare provider profile · identity verified
Angela N Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1740287838
Verified facts
What the public records show
CMS Open Payments records show Angela N Smith, M.D. received $502.13 in general payments during 2025 across 21 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $179.46 | 35.7% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $138.88 | 27.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.87 | 15.3% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.28 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.67 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.60 | 3.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.44 | 3.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.93 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $402.14 | 20 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $179.46 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.20 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
89 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 528 | 154 |
| Tramadol Hcl | Tramadol Hcl | 444 | 113 |
| Famotidine | Famotidine | 401 | 142 |
| Gabapentin | Gabapentin | 353 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 273 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 85 |
| Lisinopril | Lisinopril | 257 | 82 |
| Telmisartan | Telmisartan | 241 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 228 | 66 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 214 | 42 |
| Raloxifene Hcl | Raloxifene Hcl | 206 | 71 |
| Glimepiride | Glimepiride | 186 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 59 |
| Carvedilol | Carvedilol | 143 | 46 |
| Methocarbamol | Methocarbamol | 143 | 59 |
| Metoclopramide Hcl | Metoclopramide Hcl | 138 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 55 |
| Memantine Hcl | Memantine Hcl | 124 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 39 |
| Buspirone Hcl | Buspirone Hcl | 119 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 42 |
| Losartan Potassium | Losartan Potassium | 118 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 43 |
| Potassium Chloride | Potassium Chloride | 111 | 38 |
| Mounjaro | Tirzepatide | 108 | 26 |
| Allopurinol | Allopurinol | 106 | 35 |
| Montelukast Sodium | Montelukast Sodium | 104 | 34 |
| Nifedipine Er | Nifedipine | 101 | 31 |
| Trazodone Hcl | Trazodone Hcl | 100 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 36 |
| Cimetidine | Cimetidine | 98 | 33 |
| Lovastatin | Lovastatin | 98 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 27 |
| Rybelsus | Semaglutide | 89 | 27 |
| Prednisone | Prednisone | 87 | 71 |
| Ozempic | Semaglutide | 84 | 17 |
| Felodipine Er | Felodipine | 80 | 28 |
| Estradiol | Estradiol | 74 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Meclizine Hcl | Meclizine Hcl | 73 | 38 |
| Finasteride | Finasteride | 72 | 24 |
| Simvastatin | Simvastatin | 72 | 21 |
| Baclofen | Baclofen | 71 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 26 |
| Furosemide | Furosemide | 64 | 23 |
| Alendronate Sodium | Alendronate Sodium | 60 | 27 |
| Pregabalin | Pregabalin | 60 | 25 |
| Mirtazapine | Mirtazapine | 58 | 23 |
| Atenolol | Atenolol | 56 | 14 |
| Spironolactone | Spironolactone | 56 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | 13 |
| Bumetanide | Bumetanide | 48 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 26 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Fenofibrate | Fenofibrate,micronized | 45 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 18 |
| Sertraline Hcl | Sertraline Hcl | 44 | 14 |
| Temazepam | Temazepam | 43 | 15 |
| Ezetimibe | Ezetimibe | 39 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 39 | 11 |
| Megestrol Acetate | Megestrol Acetate | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 14 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Folic Acid | Folic Acid | 36 | 11 |
| Xarelto | Rivaroxaban | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 13 |
| Azithromycin | Azithromycin | 30 | 29 |
| Januvia | Sitagliptin Phosphate | 30 | 12 |
| Omeprazole | Omeprazole | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Eliquis | Apixaban | 29 | 12 |
| Ketoconazole | Ketoconazole | 29 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | 11 |
| Linzess | Linaclotide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | 13 |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 20 |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | 11 |
| Tadalafil | Tadalafil | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.13 · 21 records | Bayer Healthcare Pharmaceuticals Inc. | Cologuard Collection Kit, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, TZIELD, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error